drugset
drugset / Trial / NCT03739632

Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets

NCT03739632 ↗

Phase 2 Completed 240 enrolled Zhejiang Huahai Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total scores from baseline to week 6.

Timeline

Start
2018-11-30
Primary completion
2019-12-18
Completion
2019-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypidone Unknown 5 mg Oral
Subject Hypidone Unknown 10 mg Oral
Subject Hypidone Unknown 20 mg Oral

Indications

major depressive disorder